Építés alatt – nem éles oldal
Belépés
Csak meghívásos3. fázis

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.

A legfontosabb adatok

Ki végzi
Lupin Ltd.
Hol
Belgium, Dánia, Egyesült Királyság, Németország, Olaszország és Spanyolország6 helyszín, 6 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Csak meghívásos
Fázis
3. fázis
Résztvevők
176 fő, tervezett
Kezdés
2025. szept. 12.
Várható befejezés
2028. júl. 6.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Mexiletine granules for prolonged-release oral suspension
A regiszteradat frissítve
2026. január 26.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people with myotonic dystrophy type 1 or type 2 who have completed the MEX-DM-302 study. They will take mexiletine PR once a day.

Életkor
16 years and older
Nem
Male and female. Women cannot be pregnant.
A betegség stádiuma
Myotonic dystrophy type 1 (DM1) or type 2 (DM2), confirmed by a genetic test. People with DM1 need a muscle impairment (MIRS) score of 2, 3 or 4. People need enough finger strength to grip a hand-strength device.
Korábbi kezelés
People must have completed the MEX-DM-302 study. No anti-myotonic treatment within 4 weeks before the start, or 5 half-lives if that is longer.
Biomarker vagy leletérték
Genetic test confirming DM1 or DM2. BMI of 18.5 kg/m2 to 30 kg/m2, and weight of at least 45 kg (99 lb). Blood potassium from 3.5 to 5.0 mmol/L and magnesium of at least 1.7 mg/dL.

A részvétel fő kizáró okai

  • Pregnant or breastfeeding
  • Serious heart problems, heart rhythm problems, a pacemaker or an implanted defibrillator
  • Severe kidney problems (GFR < 30 mL/min) or liver tests > 3 times the upper limit of normal
  • Using a wheelchair or confined to bed, or more than 5 falls in the past 12 months
  • Allergy to mexiletine or local anesthetics

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • DM1 or DM2 diagnosis confirmed genetically
  • Ability to comprehend and willingness to sign an informed consent (ICF) or ICF of the parent(s)/legal guardian and written assent from the patient (if patient < 18 years of age)
  • Ability to understand the study requirements including intention to stay in the study until the end-of-study visit at 26 weeks of treatment
  • Male or non-pregnant female ≥16 years of age
  • Body Mass Index (BMI) of 18.5 kg/m2 to 30 kg/m2, and weight ≥45 kg
  • Female patients of childbearing potential must be using a highly effective form of birth control for the duration of the study and for at least 7 days after last dose of study drug
  • No significant cardiac abnormalities as determined by a cardiologist's assessment
  • Have sufficient finger flexor strength to grasp the handle of the dynamometer used to measure myotonia
  • DM1 patients only - Muscular impairment rating scale (MIRS) score of 2, 3 or 4

Ki nem vehet részt

  • Have any one of the following medical conditions: uncontrolled diabetes mellitus, cancer other than skin cancer less than five years previously (e.g., basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC) of skin allowed), multiple sclerosis, seizure disorders, or other serious medical illness
  • Intake of any anti-myotonic treatment within 4 weeks prior to baseline (Day 1) or 5 half-lives, whichever is longer such as metformin, such as propafenone, flecainide, lamotrigine, carbamazepine or any other channel-blocker/ anticonvulsive drugs
  • Use of any concomitant medications that could increase the cardiac risk
  • Participation in another interventional clinical study during the last 3 months or 5 half-lives of the investigational medicinal product, whichever is longer (with the exception of participation in the previous MEX-DM-302 study)
  • Medical conditions which could interfere with muscle function such as infections, trauma, fractures, or planned surgery
  • Medical conditions that could affect hand functioning including but not limited to rheumatoid arthritis, Dupuytren's contracture, hand deformity, etc
  • Severe arthritis or medical condition (other thanDM1/DM2) that would significantly impact ambulation
  • Known allergy to mexiletine or any local anesthetics
  • Severe renal impairment (glomerular filtration rate (GFR) < 30 mL/min)
  • Preexisting elevated liver function tests > 3 times the upper limit of normal (ULN) on Day 1 (alanine transaminase (ALT)/aspartate transaminase (AST), gamma-glutamyl transferase (GGT)) and/or any abnormal chemistry, hematology or urine lab considered clinically significant by investigator
  • Serum potassium values < 3.5 mmol/L or > 5.0 mmol/L or serum magnesium values < 1.7 mg/dL. Electrolytic imbalance such as hypokalaemia, hyperkalaemia or hypomagnesaemia may increase the proarrhythmic effects of mexiletine. Electrolyte imbalances need to be corrected before administering mexiletine and will be monitored throughout treatment
  • Any cardiac safety associated condition including any of the following criteria detected by cardiac evaluations including 24-hr Holter monitor, echocardiogram and clinical evaluations:; PR interval ≥240 ms or QRS duration ≥120 ms on resting ECG; Personal history of 3rd degree or 2nd degree type 2 atrioventricular block or sinus node dysfunction with pauses ≥3 seconds, complete bundle branch block, bifascicular and trifascicular block or any heart block susceptible to evolve to complete heart block; Personal history of sustained atrial fibrillation, flutter or tachycardia (duration >30 seconds); Personal history of non-sustained (ventricular triplets or more) or sustained ventricular tachycardia; Myocardial infarction (acute or past) or coronary artery stenosis >50%, presence of abnormal Q waves; New York Heart Association (NYHA) Class II to IV heart failure; Left ventricular systolic dysfunction with ejection fraction <50%; Sinus node dysfunction (including ECG sinus rate <50 beats per minute (BPM)); Co-administration of antiarrhythmics inducing torsades de pointes (class Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant); Co-administration of other classes of antiarrhythmics (class Ib: lidocaine, phenytoin, tocainide; class II: propranolol, esmolol, timolol, metoprolol, atenolol, carvedilol, bisoprolol, nebivolol; class IV: verapamil, diltiazem); Patients with implantable cardioverter defibrillators (ICDs) and pacemakers are excluded; Presence of symptomatic coronary artery disease
  • Are pregnant or lactating
  • High incidence of falls or fall-associated fractures (>5 falls during the past 12 months)
  • Wheelchair-bound or bed-ridden

Hol van ez a vizsgálat?

6 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is an open-label extension study intended to evaluate the long-term safety and efficacy of mexiletine PR in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed the parent study MEX-DM-302.

A vizsgálat csoportja

  • Mexiletine prolonged-release (PR)Egyéb csoport

    Mexiletine PR 167 mg (mexiletine HCl 200 mg) Mexiletine PR 333 mg (mexiletine HCl 400 mg) OR Mexiletine PR 500 mg (mexiletine HCl 600 mg)

    Kezelés: Mexiletine granules for prolonged-release oral suspension

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed the MEX-DM-302 Study (ATLAS Study)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. január 26.